BioSpace News Archive

Stryker announced today that it has received U.S. Food and Drug Administration (FDA) approval for an expanded indication of its Neuroform Atlas Stent System, becoming the first and only adjunctive stent approved for use in the posterior (back of the brain) circulation. Aneurysms in the posterior circulation rupture more

Surface Plasmon Resonance is a phenomenon of squeezing light to a tiny volume, causing biomolecules to get trapped across a surface, which in turn enables their study under a microscope.

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, and Mark Hahn, Chief Financial Officer, will present a company overview at the following virtual investor conferences in August 2020

ASLAN Pharmaceuticals, a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, announced that Dr Kenneth Kobayashi has been appointed Chief Medical Officer.

The MEDICREA® Group, pioneering the transformation of spinal surgery through Artificial Intelligence, predictive modeling and patient specific implants with its UNiD™ ASI proprietary software platform, services and technologies, announces the appointment of an independent expert.

Quotient Limited, a commercial-stage diagnostics company, headquartered in Eysins, Switzerland, reported its first quarter fiscal 2021 results and summarized recent key developments.

Freeline Therapeutics Holdings plc, a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, announced that it has launched the roadshow for its initial public offering in the United States of up to 7,352,941 American Depositary Shares representing 7,352,941 ordinary shares.

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it will report financial results and provide an update on its development programs pre-market on August 10, 2020.

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results for the second quarter ended June 30, 2020 before the U.S. financial markets open on Monday, August 10, 2020. Management will host a conference call on August 10, 2020 at 8:30 a.m. ET to discuss these results

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at the BTIG Virtual Biotechnology Conference on Monday, August 10, 2020, at 1:00 p.m. ET. A live webcast of the presentation will be available on the Company’s website at